537 related articles for article (PubMed ID: 20886392)
1. TA-CIN, a vaccine incorporating a recombinant HPV fusion protein (HPV16 L2E6E7) for the potential treatment of HPV16-associated genital diseases.
Hibbitts S
Curr Opin Mol Ther; 2010 Oct; 12(5):598-606. PubMed ID: 20886392
[TBL] [Abstract][Full Text] [Related]
2. Vaccination of healthy volunteers with human papillomavirus type 16 L2E7E6 fusion protein induces serum antibody that neutralizes across papillomavirus species.
Gambhira R; Gravitt PE; Bossis I; Stern PL; Viscidi RP; Roden RB
Cancer Res; 2006 Dec; 66(23):11120-4. PubMed ID: 17145854
[TBL] [Abstract][Full Text] [Related]
3. Immunological and clinical responses in women with vulval intraepithelial neoplasia vaccinated with a vaccinia virus encoding human papillomavirus 16/18 oncoproteins.
Davidson EJ; Boswell CM; Sehr P; Pawlita M; Tomlinson AE; McVey RJ; Dobson J; Roberts JS; Hickling J; Kitchener HC; Stern PL
Cancer Res; 2003 Sep; 63(18):6032-41. PubMed ID: 14522932
[TBL] [Abstract][Full Text] [Related]
4. Vaccination with HPV16 L2E6E7 fusion protein in GPI-0100 adjuvant elicits protective humoral and cell-mediated immunity.
Karanam B; Gambhira R; Peng S; Jagu S; Kim DJ; Ketner GW; Stern PL; Adams RJ; Roden RB
Vaccine; 2009 Feb; 27(7):1040-9. PubMed ID: 19095032
[TBL] [Abstract][Full Text] [Related]
5. Vaccinia-expressed human papillomavirus 16 and 18 e6 and e7 as a therapeutic vaccination for vulval and vaginal intraepithelial neoplasia.
Baldwin PJ; van der Burg SH; Boswell CM; Offringa R; Hickling JK; Dobson J; Roberts JS; Latimer JA; Moseley RP; Coleman N; Stanley MA; Sterling JC
Clin Cancer Res; 2003 Nov; 9(14):5205-13. PubMed ID: 14614000
[TBL] [Abstract][Full Text] [Related]
6. Technology evaluation: T-cell activator, Xenova.
Knutson KL
Curr Opin Mol Ther; 2001 Dec; 3(6):585-8. PubMed ID: 11804273
[TBL] [Abstract][Full Text] [Related]
7. Immune control of human papillomavirus (HPV) associated anogenital disease and potential for vaccination.
Stern PL
J Clin Virol; 2005 Mar; 32 Suppl 1():S72-81. PubMed ID: 15753015
[TBL] [Abstract][Full Text] [Related]
8. Human papillomavirus vaccines.
Breitburd F; Coursaget P
Semin Cancer Biol; 1999 Dec; 9(6):431-44. PubMed ID: 10712890
[TBL] [Abstract][Full Text] [Related]
9. Induction of CD4-independent E7-specific CD8+ memory response by heat shock fusion protein.
Liu H; Wu BH; Rowse GJ; Emtage PC
Clin Vaccine Immunol; 2007 Aug; 14(8):1013-23. PubMed ID: 17596433
[TBL] [Abstract][Full Text] [Related]
10. Optimization of heterologous DNA-prime, protein boost regimens and site of vaccination to enhance therapeutic immunity against human papillomavirus-associated disease.
Peng S; Qiu J; Yang A; Yang B; Jeang J; Wang JW; Chang YN; Brayton C; Roden RBS; Hung CF; Wu TC
Cell Biosci; 2016; 6():16. PubMed ID: 26918115
[TBL] [Abstract][Full Text] [Related]
11. Optimal induction of HPV DNA vaccine-induced CD8+ T cell responses and therapeutic antitumor effect by antigen engineering and electroporation.
Seo SH; Jin HT; Park SH; Youn JI; Sung YC
Vaccine; 2009 Sep; 27(42):5906-12. PubMed ID: 19651174
[TBL] [Abstract][Full Text] [Related]
12. Pre-clinical safety and efficacy of TA-CIN, a recombinant HPV16 L2E6E7 fusion protein vaccine, in homologous and heterologous prime-boost regimens.
van der Burg SH; Kwappenberg KM; O'Neill T; Brandt RM; Melief CJ; Hickling JK; Offringa R
Vaccine; 2001 Jun; 19(27):3652-60. PubMed ID: 11395199
[TBL] [Abstract][Full Text] [Related]
13. Prime-boost vaccination strategy in women with high-grade, noncervical anogenital intraepithelial neoplasia: clinical results from a multicenter phase II trial.
Fiander AN; Tristram AJ; Davidson EJ; Tomlinson AE; Man S; Baldwin PJ; Sterling JC; Kitchener HC
Int J Gynecol Cancer; 2006; 16(3):1075-81. PubMed ID: 16803488
[TBL] [Abstract][Full Text] [Related]
14. Induction of tumor-specific CD4+ and CD8+ T-cell immunity in cervical cancer patients by a human papillomavirus type 16 E6 and E7 long peptides vaccine.
Welters MJ; Kenter GG; Piersma SJ; Vloon AP; Löwik MJ; Berends-van der Meer DM; Drijfhout JW; Valentijn AR; Wafelman AR; Oostendorp J; Fleuren GJ; Offringa R; Melief CJ; van der Burg SH
Clin Cancer Res; 2008 Jan; 14(1):178-87. PubMed ID: 18172269
[TBL] [Abstract][Full Text] [Related]
15. Vaccination against HPV-16 oncoproteins for vulvar intraepithelial neoplasia.
Kenter GG; Welters MJ; Valentijn AR; Lowik MJ; Berends-van der Meer DM; Vloon AP; Essahsah F; Fathers LM; Offringa R; Drijfhout JW; Wafelman AR; Oostendorp J; Fleuren GJ; van der Burg SH; Melief CJ
N Engl J Med; 2009 Nov; 361(19):1838-47. PubMed ID: 19890126
[TBL] [Abstract][Full Text] [Related]
16. A novel, broad spectrum therapeutic HPV vaccine targeting the E7 proteins of HPV16, 18, 31, 45 and 52 that elicits potent E7-specific CD8T cell immunity and regression of large, established, E7-expressing TC-1 tumors.
Wick DA; Webb JR
Vaccine; 2011 Oct; 29(44):7857-66. PubMed ID: 21816200
[TBL] [Abstract][Full Text] [Related]
17. Vaccines for preventing HPV-related anogenital infection and neoplasia.
Ferris DG
J Am Osteopath Assoc; 2006 Mar; 106(3 Suppl 1):S9-13. PubMed ID: 16729555
[TBL] [Abstract][Full Text] [Related]
18. Local HPV Recombinant Vaccinia Boost Following Priming with an HPV DNA Vaccine Enhances Local HPV-Specific CD8+ T-cell-Mediated Tumor Control in the Genital Tract.
Sun YY; Peng S; Han L; Qiu J; Song L; Tsai Y; Yang B; Roden RB; Trimble CL; Hung CF; Wu TC
Clin Cancer Res; 2016 Feb; 22(3):657-69. PubMed ID: 26420854
[TBL] [Abstract][Full Text] [Related]
19. Review of current knowledge on HPV vaccination: an appendix to the European Guidelines for Quality Assurance in Cervical Cancer Screening.
Arbyn M; Dillner J
J Clin Virol; 2007 Mar; 38(3):189-97. PubMed ID: 17258503
[TBL] [Abstract][Full Text] [Related]
20. Immunological responses in women with human papillomavirus type 16 (HPV-16)-associated anogenital intraepithelial neoplasia induced by heterologous prime-boost HPV-16 oncogene vaccination.
Smyth LJ; Van Poelgeest MI; Davidson EJ; Kwappenberg KM; Burt D; Sehr P; Pawlita M; Man S; Hickling JK; Fiander AN; Tristram A; Kitchener HC; Offringa R; Stern PL; Van Der Burg SH
Clin Cancer Res; 2004 May; 10(9):2954-61. PubMed ID: 15131030
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
